Author : adminDate : 2019-10-16 00:00

HLB, Elevar agree to triangular merger deal to speed up Rivoceranib development

South Korea’s HLB is gaining speed in its plan to commercially develop a targeted anticancer therapy called Rivoceranib through a triangular merger involving its U.S. affiliate and the drug’s original developer Elevar.


Source: https://pulsenews.co.kr/view.php?year=2019&no=839136